Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with…
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition
Lantern Pharma, Inc. (NASDAQ: LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.'s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD). LP-284 is an investigational small-molecule…
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
New company established by a leading international life sciences investment firm Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has…
Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results
Press Release – No. 3 / 2026 Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Copenhagen, Denmark, February 12, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078)…
Uttar Pradesh govt's pharma investment kitty hits ₹38,000 crore
While 210 investment proposals to the tune of ₹28,000 cr were received following the Uttar Pradesh Global Investors' Summit (GIS) in 2024, the state secured about a dozen fresh investment proposals at the UP Pharma Conclave in Lucknow…
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call February 11, 2026 4:30 PM EST Chad Fugure - Vice President of Investor Relations Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smith - CFO, Executive VP &…
Pharma taking PBAC to court over knockback
PERTH-BASED Lawley Pharmaceuticals has lodged an application in the Federal Court of Australia seeking judicial review of the decision by the Pharmaceutical Benefits Advisory Committee (PBAC) in Nov 2025 to not recommend listing of AndroFeme 1, a…
NATCO Pharma Q3 PAT up
NATCO Pharma has posted a net profit of ₹151.3 crore in the third quarter ended December 31, 2025, as against ₹132.4 crore in the comparable quarter last year. It registered a revenue of ₹647.30 crore (₹475 crore) in the…
Royalty Pharma targets 3%-8% royalty receipts growth in 2026 while advancing $4.7B in transactions (NASDAQ:RPRX)
Earnings Call Insights: Royalty Pharma (RPRX) Q4 2025 CEO Pablo Legorreta stated that '2025 was truly a landmark year for Royalty Pharma as we executed successfully towards our goal to be the premier capital allocator in life sciences with Seeking…
Natco Pharma consolidated net profit rises 13.91% in the December 2025 quarter
Last Updated: Feb 12 2026 | 4:11 PM IST Sales rise 36.33% to Rs 647.30 crore Net profit of Natco Pharma rose 13.91% to Rs 151.50 crore in the quarter ended December 2025 as against Rs 133.00 crore during the previous quarter ended December 2024.
'Not an exit': Founder says USV deal signals pharma validation for nutraceuticals
The sale of 79 per cent stake for a consideration of ₹1,583 crore in Wellbeing Nutrition to pharma major USV is not a founder exit but a strategic partnership to scale within a pharmaceutical ecosystem, according to Avnish Chhabria, Founder…
Pharma major USV to acquire 79% stake in Wellbeing Nutrition at ₹1,583-cr valuation
USV, a pharmaceutical and biotechnology company, will acquire a 79 per cent stake in Wellbeing Nutrition at a valuation of ₹1,583 crore. USV has signed a definitive agreement to acquire a 79 per cent equity stake in Nutritionalab Pvt Ltd…
HC Wainwright Predicts Nuvectis Pharma Q1 Earnings
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Nuvectis Pharma in a research note issued on Wednesday, February 11th. HC Wainwright analyst J. Pantginis anticipates that…
Wedbush Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its target price raised by equities research analysts at Wedbush from $240.00 to $273.00 in a research note issued on Thursday, Marketbeat.com reports. The firm currently has an 'outperform'…
Zealand Pharma A/S (ZLDPF) to Release Earnings on Thursday
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) is expected to be posting its results before the market opens on Thursday, February 19th. Analysts expect Zealand Pharma A/S to post earnings of ($1.34) per share for the quarter. Zealand Pharma…
Receive a Daily briefing on Pharma Industry News
Get Started